Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III equivalence study of TRS003 versus Avastin with paclitaxel-carboplatin in advanced non-squamous non-small cell lung cancer
CTR20191049Phase 3Terminated
- Sponsor
- Teruisi Biopharma
- Start
- Aug 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of RPH-001 in non-small cell lung cancer (NSCLC), sponsored by Teruisi Biopharma. Started Aug 2020; status: terminated.
02
Drugs
RPH-001
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20191049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20191049.